Women with high blood pressure get different treatment to men
Women who are treated for high blood pressure are not given the same medication as men, nor do they hit the treatment targets as often. This is revealed in a thesis from the Sahlgrenska Academy, including studies of over 40,000 patients.
High blood pressure is one of the most common risk factor for cardiovascular events such as stroke, heart failure and heart attack in both women and men. According to WHO, raised blood pressure is estimated to cause 7.5 million deaths worldwide, about 12.8% of the total of all deaths.
A thesis from the University of Gothenburg's Sahlgrenska Academy looks at 40,825 Swedish patients treated for high blood pressure in primary care. It shows that women and men are prescribed different medication to bring down their blood pressure. Women are also less likely than men to hit the general treatment target of blood pressure below 140/90 mm Hg, which is the threshold for high blood pressure.
The thesis shows that women are more often prescribed diuretic medication while men are given ACE inhibitors (which block an enzyme in the kidneys).
"International guidelines recommend that patients with both high blood pressure and diabetes be treated with ACE inhibitors," says doctoral student and medical doctor Charlotta Ljungman, author of the thesis. "But our study shows that women are less likely to be given this treatment. What's more, this discrepancy can't be explained away by differences in other concurrent cardiovascular disorders."
The thesis also shows that the differences in treatment between women and men are greater in patients with limited education.
The fact that women are less likely to reach the target blood pressure is partly because they are generally older when diagnosed with high blood pressure.
"But this shouldn't make a difference, as previous studies have shown that older patients with high blood pressure also benefit considerably from treatment to lower their blood pressure, not least to prevent the development of disorders such as stroke, dementia and heart failure," says Charlotta Ljungman.
Women are generally less likely to be affected by cardiovascular disease, and also succumb later in life. Charlotta Ljungman believes that this could be one of the reasons why the healthcare system underestimates the risk of future cardiovascular disease in women.
"The key thing when treating high blood pressure is to reach target blood pressure," says Charlotta Ljungman. "The fact that women do so less often than men is remarkable, and steps must be taken to improve treatment."
The thesis Treatment of hypertension in women and men will be publicly defended on 19 September.
Link to thesis: http://hdl.handle.net/2077/35942
For further information, please contact:
Charlotta Ljungman, doctoral student at the Sahlgrenska Academy and cardiologist at Sahlgrenska University Hospital
+46 (0)709 667 662
+46 (0)31 342 7589
charlotta.ljungman@vgregion.se
Lead supervisor: Karin Manhem, professor and consultant, karin.manhem@vgregion.se, +46 (0)709 310 568
Press Officer
Krister Svahn
Sahlgrenska Academy, University of Gothenburg
46766-18 38 69
4631-786 3869
krister.svahn@sahlgrenska.gu.se
The Sahlgrenska Academy is the faculty of health sciences at the University of Gothenburg. Education and research are conducted within the fields of pharmacy, medicine, odontology and health care sciences. About 4,000 undergraduate students and 1,200 postgraduate students are enrolled at Sahlgrenska Academy. Around 1,400 people work at the Sahlgrenska Academy, 850 of them are researchers and/or teachers. 2013 Sahlgrenska Academy had a turnover of 2,4 billion SEK.
Tags:
